Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Black Diamond Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 43.05%, while the net margin is 53.55%. These profitability ratios, combined with a Return on Equity (ROE) of 19.23%, provide a clear picture of how effectively BDTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BDTX competes directly with industry leaders such as UNCY and CRBU. With a market capitalization of $151.05M, it holds a leading position in the sector. When comparing efficiency, BDTX's gross margin of 100.00% stands against UNCY's N/A and CRBU's 100.00%. Such benchmarking helps identify whether Black Diamond Therapeutics Inc is trading at a premium or discount relative to its financial performance.
